Open AccessEvaluation of the Role of Ormeloxifene in Abnormal Uterine Bleeding
Author(s) -
Ritu Sharma,
Savita Rani Singhal
Publication year - 2017
Publication title -
journal of safoms
Language(s) - English
Resource type - Journals
eISSN - 2319-9830
pISSN - 2319-846X
DOI - 10.5005/jp-journals-10032-1117
Subject(s) - medicine , metrorrhagia , nausea , gynecology , menstruation , amenorrhea , adverse effect , side effect (computer science) , obstetrics , surgery , family planning , pregnancy , research methodology , computer science , population , environmental health , biology , genetics , programming language
Aim This is a prospective study to find the effect of ormeloxifene on menstrual blood loss and its side effects in patients with abnormal uterine bleeding (AUB). Materials and methods Fifty women in the age group of 30 to 52 years with AUB were enrolled in the study. After baseline assessment, each patient was given 60 mg of ormeloxifene orally twice a week for first 3 months, then once a week for the next 3 months. The patients were followed up after 1, 3, and 6 months. The effect of ormeloxifene was evaluated by a change in the pictorial blood loss assessment chart (PBAC) score, passage of clots during menstruation, hemoglobin level, endometrial thickness (ET), and dysmenorrhea. Side effects of the drug were also noted at each visit; p-value < 0.05 was taken as significant. Results There was statistically significant reduction in median PBAC score from baseline 360 to 113, 73, and 41.5 after 1, 3, and 6 months. There was significant reduction in ET, passage of clots, and dysmenorrhea at each visit. Mean hemoglobin level increased significantly by 1.56 gm% after 6 months treatment. Adverse effects included amenorrhea (28%), ovarian cyst (11.3%), nausea (4.5%), headache (2%), and weight gain (4.5%). There was no major side effect requiring termination of treatment. Conclusion Ormeloxifene is a safe and efficacious alternative for medical therapy in the management of AUB. Clinical significance Ormeloxifene can be used in women with AUB to avoid the side effects of hormonal treatment and unnecessary hysterectomies. How to cite this article Sharma R, Singhal SR. Evaluation of the Role of Ormeloxifene in Abnormal Uterine Bleeding. J South Asian Feder Menopause Soc 2017;5(2):107-110.